 The European Commission has approved Xeris Pharmaceuticals Incs NASDAQ: XERS Ogluo glucagon injection to treat severe hypoglycemia in adults, adolescents, and children aged two years and over with diabetes mellitus. Hypoglycemia low blood sugar level is a complication of glucose-lowering therapy. 